DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study of Investigational Drug in Osteoporosis (MK-0217-908)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Postmenopausal Osteoporosis

Intervention: Placebo (Drug); ibandronate (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Merck Sharp & Dohme Corp.

Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck Sharp & Dohme Corp.


The purpose of this study is to evaluate the efficacy and safety of an investigational drug in postmenopausal women with osteoporosis. The primary hypothesis of this study is that in postmenopausal women with osteoporosis, oral monthly ibandronate, at doses of 100 mg and 150 mg, does not achieve persistence in reduction of bone resorption throughout the monthly dosing interval, as demonstrated by a larger change in the serum carboxyterminal crosslinked telopeptide of Type I collagen (CTX-I) log-transformed fraction from baseline four weeks post dose compared to one week post dose, during the third month of treatment, in the participants taking ibandronate than in the participants taking placebo.

Clinical Details

Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Persistence of the Effect of Oral Monthly Ibandronate on Bone Reception in Postmenopausal Women in Osteoporosis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Change in serum levels of CTX-I (log-transformed fraction) from Week 9 to Week 12


Minimum age: 50 Years. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria: - postmenopausal for at least 3 years, with osteoporosis at any of the

following sites: [BMD > 2. 0 standard deviations below young normal mean bone mass for the hip trochanter, PA lumbar spine (L1 to L4), total hip, or femoral neck based on the normative database provided by each individual manufacturer].

- willing to take study-supplied calcium and vitamin D supplement (or equivalent) and

to discontinue any non-study calcium supplements for run-in period and the duration

of the study. Exclusion Criteria: - pregnant or lactating, or of childbearing


- participated in another therapeutic trial with an investigational compound within 30

days of randomization.

- history of hypersensitivity to any component of ibandronate tablets or has hereditary

problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

- an abnormality of the esophagus which delays esophageal emptying such as stricture or


- unable to stand or sit upright for at least 60 minutes once a month.

- current use of illicit drugs, or history of drug or alcohol abuse within the past

five years.

- has any of the following: hypocalcemia; any severe malabsorption syndrome; moderate

or severe hypertension which is uncontrolled; new onset angina or myocardial infarction within six months of entry into the study; evidence for impaired renal function; organ transplantation; or other significant end organ diseases (genitourinary, cardiovascular, endocrine, hepatic, psychiatric, renal, hematologic, or pulmonary).

- history of or evidence of metabolic bone disease (other than postmenopausal bone


- clinical fracture in the past year.

- is receiving or has received treatment prior to randomization which might influence

bone turnover.

- is receiving or expected to receive during the course of the study any medication

(other than study medication) which might alter bone or calcium metabolism, including Vitamin A in excess of 10,000 IU per day or Vitamin D in excess of 5000 IU per day, calcitonin, phenytoin, heparin, or lithium.

Locations and Contacts

Additional Information

Starting date: December 2004
Last updated: November 7, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017